Current Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2006 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Tumor-Associated Molecules Lead the Way to New Therapies for Small Cell Lung Cancer.
Journal Article JCO Oncol Pract · April 2, 2025 Full text Link to item CitePerioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.
Journal Article J Immunother Cancer · February 4, 2025 BACKGROUND: Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. METHODS: This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, cli ... Full text Link to item CiteComplement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.
Journal Article Nat Commun · January 2, 2025 GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b study dose escalation trial of GT103 in re ... Full text Open Access Link to item CiteRecent Grants
Safety, Efficacy, and Tumor Immune Microenvironment Changes with Neoadjuvant Chemotherapy and Cemiplimab with or without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2024 - 2030DS7300-127 HAB08860
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2022 - 2027BMS 050
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2021 - 2026View All Grants
Education, Training & Certifications
Vanderbilt University ·
1986
M.D.
University of California, Irvine ·
1983
Ph.D.